First-line bevacizumab for ovarian cancer—new standard of care?

被引：0
|
作者：
Susana Banerjee
Stan B. Kaye
机构：
[1] The Royal Marsden NHS Foundation Trust,
[2] The Institute of Cancer Research and Royal Marsden Hospital,undefined
来源：
Nature Reviews Clinical Oncology | 2012年 / 9卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Demonstration of the clinically significant activity of bevacizumab in advanced-stage ovarian cancer has attracted a great deal of interest. Here, we summarize the two positive phase III trials that led to EMA approval of bevacizumab as first-line therapy and discuss the optimum use of the drug in this disease.boxed-text
引用
收藏
页码：194 / 196
页数：2
相关论文
共 50 条
  • [1] GYNECOLOGICAL CANCER First-line bevacizumab for ovarian cancer-new standard of care?
    Banerjee, Susana
    Kaye, Stan B.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (04) : 194 - 196
  • [2] First-Line Therapy with Bevacizumab - Standard in advanced Ovarian Carcinoma
    Pohlmann, Birgit-Kristin
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (06) : 382 - 383
  • [3] Bevacizumab in the First-line Treatment of advanced Ovarian Cancer
    Mallmann, Michael R.
    Alakus, Hakan
    Mallmann, Peter
    Bruns, Christiane
    [J]. ONKOLOGE, 2019, 25 (11): : 1020 - 1021
  • [4] First-line PARP inhibition in ovarian cancer — standard of care for all?
    Susana N. Banerjee
    Christopher J. Lord
    [J]. Nature Reviews Clinical Oncology, 2020, 17 : 136 - 137
  • [5] First-line PARP inhibition in ovarian cancer - standard of care for all?
    Banerjee, Susana N.
    Lord, Christopher J.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (03) : 136 - 137
  • [6] Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
    Ray-Coquard, I.
    Pautier, P.
    Pignata, S.
    Perol, D.
    Gonzalez-Martin, A.
    Berger, R.
    Fujiwara, K.
    Vergote, I.
    Colombo, N.
    Maenpaa, J.
    Selle, F.
    Sehouli, J.
    Lorusso, D.
    Alia, E. M. Guerra
    Reinthaller, A.
    Nagao, S.
    Lefeuvre-Plesse, C.
    Canzler, U.
    Scambia, G.
    Lortholary, A.
    Marme, F.
    Combe, P.
    de Gregorio, N.
    Rodrigues, M.
    Buderath, P.
    Dubot, C.
    Burges, A.
    You, B.
    Pujade-Lauraine, E.
    Harter, P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25): : 2416 - 2428
  • [7] The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer
    Bookman, M. A.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 211 - 217
  • [8] FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer
    Cervantes, A.
    Prager, G. W.
    [J]. ESMO OPEN, 2023, 8 (02)
  • [9] First-line treatment of women with advanced ovarian cancer: focus on bevacizumab
    Marchetti, Claudia
    Muzii, Ludovico
    Romito, Alessia
    Panici, Pierluigi Benedetti
    [J]. ONCOTARGETS AND THERAPY, 2019, 12 : 1095 - 1103
  • [10] SLOVENIAN EXPERIENCE WITH BEVACIZUMAB IN FIRST-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER
    Gregoric, B.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A53 - A54
12345